- SynonymIGF2,C11orf43,FLJ22066,FLJ44734,IGF-II,PP9974
- SourceBiotinylated Human IGF-II, Avitag,Fc Tag (IG2-H82F9) is expressed from human 293 cells (HEK293). It contains AA Ala 25 - Glu 91 (Accession # P01344-1).Predicted N-terminus: GlyRequest for sequence
- Molecular Characterization
This protein carries an Avi tag (Avitag™) at the N-terminus, followed by a human IgG1 Fc tag.
The protein has a calculated MW of 35.3 kDa. As a result of glycosylation, the protein migrates as 40 kDa under reducing (R) condition, and 66 kDa under non-reducing (NR) condition (SDS-PAGE).
- BiotinylationBiotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.
- Biotin:Protein RatioThe biotin to protein ratio is 0.5-1 as determined by the HABA assay.
- EndotoxinLess than 1.0 EU per μg by the LAL method.
- Purity
>95% as determined by SDS-PAGE.
- Formulation
Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5. Normally trehalose is added as protectant before lyophilization.
Contact us for customized product form or formulation.
- Reconstitution
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
- Storage
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
- -20°C to -70°C for 12 months in lyophilized state;
- -70°C for 3 months under sterile conditions after reconstitution.
Biotinylated Human IGF-II, Avitag,Fc Tag on SDS-PAGE under reducing (R) and non-reducing (NR) conditions. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 95%.
Immobilized Human IGFBP-3, His Tag (Cat. No. IG3-H5229) at 5 μg/mL (100 μL/well) can bind Biotinylated Human IGF-II, Avitag,Fc Tag (Cat. No. IG2-H82F9) with a linear range of 0.008-0.1 μg/mL (QC tested).
- BackgroundInsulin-like growth factor 2 (IGF-2) is also known as Somatomedin-A, IGF-II, PP9974, and is one of three protein hormonesthat share structural similarity to insulin. IGF-2 exerts its effects by binding to the IGF-1 receptor. IGF2 may also bind to the IGF-2 receptor (also called the cation-independent mannose 6-phosphate receptor), which acts as a signalling antagonist; that is, to prevent IGF2 responses. The major role of IGF2 is as a growth promoting hormone during gestation. In the process of Folliculogenesis, IGF2 is created by Theca cells to act in an autocrine manner on the theca cells themselves, and in a paracrine manner on Granulosa cells in the ovary. IGF2 promotes granulosa cell proliferation during the follicular phase of the menstrual cycle, acting alongside Follicle Stimulating Hormone (FSH). After ovulation has occurred, IGF-2 promotes progesterone secretion during the luteal phase of the menstrual cycle together with Luteinizing Hormone (LH). Thus, IGF2 acts as a Co-hormone together with both FSH and LH. IGF-2may play a key role in memory and could potentially be used to treat Alzheimer"s Disease. It is sometimes produced in excess in islet cell tumours, causing hypoglycemia. Doege-Potter syndrome is a paraneoplastic syndrome in which hypoglycemia is associated with the presence of one or more non-islet fibrous tumors in the pleural cavity. has been shown to interact with IGFBP3 and Transferrin.
- References
- (1)MacRae, Fiona , 2011, Daily Mail (London).
- (2)Balduyck B,et al., 2006, J Thorac Oncol 1 (6): 588–90.
- (3)Storch, S, et al., 2001, FEBS Lett. (Netherlands) 509 (3): 395–8.
- (4)Buckway, C K, et al., 2001, J. Clin. Endocrinol. Metab. (United States) 86 (10): 4943–50.
- (5)Twigg, S M, Baxter R C, 1998, J. Biol. Chem. (UNITED STATES) 273 (11): 6074–9.
- (6)Firth, S M; Ganeshprasad U, Baxter R C, 1998, J. Biol. Chem. (UNITED STATES) 273 (5): 2631–8.
Please contact us via TechSupport@acrobiosystems.com if you have any question on this product.
